Dimensional Fund Advisors LP Has $910,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT)

Dimensional Fund Advisors LP raised its stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 222.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 185,768 shares of the company's stock after acquiring an additional 128,190 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.32% of Rezolute worth $910,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in RZLT. JPMorgan Chase & Co. bought a new position in Rezolute during the 3rd quarter valued at $42,000. Charles Schwab Investment Management Inc. boosted its stake in Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after acquiring an additional 9,000 shares during the last quarter. American Century Companies Inc. boosted its stake in Rezolute by 62.1% during the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after acquiring an additional 24,742 shares during the last quarter. Geode Capital Management LLC boosted its stake in Rezolute by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after acquiring an additional 25,413 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in Rezolute during the 4th quarter valued at $277,000. 82.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of Rezolute in a report on Monday, April 28th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. JMP Securities increased their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a report on Thursday, February 13th. Wedbush reissued an "outperform" rating and set a $12.00 target price on shares of Rezolute in a report on Wednesday. Finally, Guggenheim reissued a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $12.14.

Rezolute Price Performance

Shares of RZLT stock traded up $0.01 during trading hours on Friday, reaching $3.57. The stock had a trading volume of 1,113,556 shares, compared to its average volume of 629,641. Rezolute, Inc. has a twelve month low of $2.22 and a twelve month high of $6.19. The firm has a 50-day simple moving average of $3.24 and a 200-day simple moving average of $4.30. The firm has a market capitalization of $216.11 million, a PE ratio of -2.93 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, equities analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Daron Evans bought 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the transaction, the chief financial officer now directly owns 237,900 shares of the company's stock, valued at approximately $687,531. This represents a 4.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The stock was bought at an average price of $2.85 per share, with a total value of $35,060.70. Following the transaction, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 39,060 shares of company stock valued at $130,694 in the last quarter. Company insiders own 18.39% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.